Treatment of haemangioma by oral prednisone therapy - A preliminary report on 9 cases

G. Boggio Robutti, L. Musio, R. Mazzola

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

9 patients affected by rapidly enlarging haemangiomas have been treated by oral prednisone administration. Among these patients, 7 were females and 2 males. The age ranged from 45 days to 2 years. Haemangiomas were of the mixed "strawberry" and cavernous type (with the exception of 1 case which was of the deep cavernous type). The haemangiomas were localized in the face or in the parotid region in 7 cases, in the vulvar region in 1 case, and in the mammary region in 1 case (female). Patients received prednisone dosages of 1.5 mg/kg daily for 3 days, then 1.0 mg/kg daily for the duration of 4 weeks in 5 cases. In 2 cases the duration was 3 weeks, and in 2 cases was 2 weeks. In 3 cases a second therapeutic course of 3 weeks was prescribed, from 3 to 1 months after the withdrawal of the first cycle. In 4 cases significant reduction of the lesion was obtained within 2 weeks of treatment, and persisted after a follow-up period of 6 months (2 cases), 3 months (1 case) and 1 month (1 case). In 4 cases the lesions ceased to increase in size and remained static after follow-up periods of 3-4 months. In 1 case the lesion was still enlarging 1 month after the withdrawal of a 3 week therapeutic course. Better results were obtained in younger patients (under 6 months of age) and in haemangiomas localized in the face or parotid region. No rebound effect was observed. On the whole, these results can be considered as positive ones, and support the impression that, in particular cases of haemangioma, prednisone may be an effective means of therapy, allowing one to adopt a waiting attitude otherwise impossible in such cases.

Original languageEnglish
Pages (from-to)95-108
Number of pages14
JournalChirurgia Plastica
Volume1
Issue number2
DOIs
Publication statusPublished - Jun 1972

Fingerprint

Hemangioma
Prednisone
Parotid Region
Therapeutics
Fragaria
Oral Administration
Breast

ASJC Scopus subject areas

  • Surgery

Cite this

Treatment of haemangioma by oral prednisone therapy - A preliminary report on 9 cases. / Robutti, G. Boggio; Musio, L.; Mazzola, R.

In: Chirurgia Plastica, Vol. 1, No. 2, 06.1972, p. 95-108.

Research output: Contribution to journalArticle

Robutti, G. Boggio ; Musio, L. ; Mazzola, R. / Treatment of haemangioma by oral prednisone therapy - A preliminary report on 9 cases. In: Chirurgia Plastica. 1972 ; Vol. 1, No. 2. pp. 95-108.
@article{5fac001a83cc4dcc9de8f363ff650557,
title = "Treatment of haemangioma by oral prednisone therapy - A preliminary report on 9 cases",
abstract = "9 patients affected by rapidly enlarging haemangiomas have been treated by oral prednisone administration. Among these patients, 7 were females and 2 males. The age ranged from 45 days to 2 years. Haemangiomas were of the mixed {"}strawberry{"} and cavernous type (with the exception of 1 case which was of the deep cavernous type). The haemangiomas were localized in the face or in the parotid region in 7 cases, in the vulvar region in 1 case, and in the mammary region in 1 case (female). Patients received prednisone dosages of 1.5 mg/kg daily for 3 days, then 1.0 mg/kg daily for the duration of 4 weeks in 5 cases. In 2 cases the duration was 3 weeks, and in 2 cases was 2 weeks. In 3 cases a second therapeutic course of 3 weeks was prescribed, from 3 to 1 months after the withdrawal of the first cycle. In 4 cases significant reduction of the lesion was obtained within 2 weeks of treatment, and persisted after a follow-up period of 6 months (2 cases), 3 months (1 case) and 1 month (1 case). In 4 cases the lesions ceased to increase in size and remained static after follow-up periods of 3-4 months. In 1 case the lesion was still enlarging 1 month after the withdrawal of a 3 week therapeutic course. Better results were obtained in younger patients (under 6 months of age) and in haemangiomas localized in the face or parotid region. No rebound effect was observed. On the whole, these results can be considered as positive ones, and support the impression that, in particular cases of haemangioma, prednisone may be an effective means of therapy, allowing one to adopt a waiting attitude otherwise impossible in such cases.",
author = "Robutti, {G. Boggio} and L. Musio and R. Mazzola",
year = "1972",
month = "6",
doi = "10.1007/BF01799090",
language = "English",
volume = "1",
pages = "95--108",
journal = "European Journal of Plastic Surgery",
issn = "0930-343X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Treatment of haemangioma by oral prednisone therapy - A preliminary report on 9 cases

AU - Robutti, G. Boggio

AU - Musio, L.

AU - Mazzola, R.

PY - 1972/6

Y1 - 1972/6

N2 - 9 patients affected by rapidly enlarging haemangiomas have been treated by oral prednisone administration. Among these patients, 7 were females and 2 males. The age ranged from 45 days to 2 years. Haemangiomas were of the mixed "strawberry" and cavernous type (with the exception of 1 case which was of the deep cavernous type). The haemangiomas were localized in the face or in the parotid region in 7 cases, in the vulvar region in 1 case, and in the mammary region in 1 case (female). Patients received prednisone dosages of 1.5 mg/kg daily for 3 days, then 1.0 mg/kg daily for the duration of 4 weeks in 5 cases. In 2 cases the duration was 3 weeks, and in 2 cases was 2 weeks. In 3 cases a second therapeutic course of 3 weeks was prescribed, from 3 to 1 months after the withdrawal of the first cycle. In 4 cases significant reduction of the lesion was obtained within 2 weeks of treatment, and persisted after a follow-up period of 6 months (2 cases), 3 months (1 case) and 1 month (1 case). In 4 cases the lesions ceased to increase in size and remained static after follow-up periods of 3-4 months. In 1 case the lesion was still enlarging 1 month after the withdrawal of a 3 week therapeutic course. Better results were obtained in younger patients (under 6 months of age) and in haemangiomas localized in the face or parotid region. No rebound effect was observed. On the whole, these results can be considered as positive ones, and support the impression that, in particular cases of haemangioma, prednisone may be an effective means of therapy, allowing one to adopt a waiting attitude otherwise impossible in such cases.

AB - 9 patients affected by rapidly enlarging haemangiomas have been treated by oral prednisone administration. Among these patients, 7 were females and 2 males. The age ranged from 45 days to 2 years. Haemangiomas were of the mixed "strawberry" and cavernous type (with the exception of 1 case which was of the deep cavernous type). The haemangiomas were localized in the face or in the parotid region in 7 cases, in the vulvar region in 1 case, and in the mammary region in 1 case (female). Patients received prednisone dosages of 1.5 mg/kg daily for 3 days, then 1.0 mg/kg daily for the duration of 4 weeks in 5 cases. In 2 cases the duration was 3 weeks, and in 2 cases was 2 weeks. In 3 cases a second therapeutic course of 3 weeks was prescribed, from 3 to 1 months after the withdrawal of the first cycle. In 4 cases significant reduction of the lesion was obtained within 2 weeks of treatment, and persisted after a follow-up period of 6 months (2 cases), 3 months (1 case) and 1 month (1 case). In 4 cases the lesions ceased to increase in size and remained static after follow-up periods of 3-4 months. In 1 case the lesion was still enlarging 1 month after the withdrawal of a 3 week therapeutic course. Better results were obtained in younger patients (under 6 months of age) and in haemangiomas localized in the face or parotid region. No rebound effect was observed. On the whole, these results can be considered as positive ones, and support the impression that, in particular cases of haemangioma, prednisone may be an effective means of therapy, allowing one to adopt a waiting attitude otherwise impossible in such cases.

UR - http://www.scopus.com/inward/record.url?scp=34250463896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250463896&partnerID=8YFLogxK

U2 - 10.1007/BF01799090

DO - 10.1007/BF01799090

M3 - Article

AN - SCOPUS:34250463896

VL - 1

SP - 95

EP - 108

JO - European Journal of Plastic Surgery

JF - European Journal of Plastic Surgery

SN - 0930-343X

IS - 2

ER -